TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12889719

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adapalene solution 0.1%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tazarotene gel 0.1%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tazarotene gel 0.05%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.1%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.025%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tretinoin gel 0.025%
Number of subjects: 42

Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 42
Study: 10392868

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8896124

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg/6 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12317784

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate vaginal cream 2%, 5 grams intravaginally at bedtime
Number of subjects: 184

Group type: COMPARATOR
Intervention: Oral metronidazole capsules, 500 mg, taken twice daily
Number of subjects: 184
Study: 6524903

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus amikacin
Number of subjects: 27
Study: 31633778

Group type: EXPERIMENTAL
Intervention: BF/EF group (breastfeeding with amino acid-based elemental formula for at least the first 3 days of life)
Number of subjects: 312

Group type: COMPARATOR
Intervention: BF plus CMF group (breastfeeding supplemented with cow's milk formula ≥5 mL/d from the first day of life to 5 months of age)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: BF/EF group
Number of subjects: 312

Group type: COMPARATOR
Intervention: BF plus CMF group
Number of subjects: 312
Study: 28082337

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP, 10‐30 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no LBPP)
Number of subjects: 15
Study: 25923487

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium-fortified yogurts (FY)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-fortified control yogurts (CY)
Number of subjects: 48
Study: 23968340

Group type: EXPERIMENTAL
Intervention: Patient-oriented self-management educational program
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual care educational program (short lecture-based)
Number of subjects: 540
Study: 21470388

Group type: EXPERIMENTAL
Intervention: Heavy Silicone Oil (HSO)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard Silicone Oil
Number of subjects: 93
Study: 19735103

Group type: EXPERIMENTAL
Intervention: Hybrid decompression
Number of subjects: 28

Group type: COMPARATOR
Intervention: Two-level corpectomy
Number of subjects: 28
Study: 18693605

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation for six months
Number of subjects: 0
Study: 15473497

Group type: EXPERIMENTAL
Intervention: Quality of Life (QL) assessment at five timepoints
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Concurrent QL estimates
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Adaptation process in early colon cancer patients
Number of subjects: 186
Study: 12441903

Group type: EXPERIMENTAL
Intervention: Formal training in CVC insertion and care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of maximal sterile barriers at insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of chlorhexidine rather than povidone-iodine for cutaneous antisepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applying a topical anti-infective cream or ointment or a chlorhexidine-impregnated dressing to the insertion site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of novel catheters with an anti-infective surface or a contamination-resistant hub
Number of subjects: 0
Study: 9391222

Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine 30 mg orally
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7882281

Group type: EXPERIMENTAL
Intervention: Lumpectomy and irradiation
Number of subjects: 573

Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 573
Study: 2296931

Group type: EXPERIMENTAL
Intervention: Single, oral high dose of vitamin A (n = 65)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (n = 69)
Number of subjects: 134
Study: 354041

Group type: EXPERIMENTAL
Intervention: Carbuterol 200 microgram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hexoprenaline 200 microgram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7043710

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release 75 mg capsule b.i.d.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional indomethacin 50 mg capsule t.i.d.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 86
Study: 31412029

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Samsung Gear Oculus headset; 21 VR experiences.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group viewing specialized health and wellness television programming.
Number of subjects: 120
Study: 29543933

Group type: EXPERIMENTAL
Intervention: 79.2 Gy radiation therapy
Number of subjects: 1532

Group type: COMPARATOR
Intervention: 70.2 Gy radiation therapy
Number of subjects: 1532
Study: 26135754

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 25 mg IV for the first week, decreasing to 12.5 mg during the 2nd week until birth
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PL) matching IV treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 48
Study: 25288473

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone antagonist (GnRH-ant)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a)
Number of subjects: 50
Study: 22712670

Group type: EXPERIMENTAL
Intervention: Propofol + Sufentanil (group SF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Propofol + Remifentanil (group RF)
Number of subjects: 46
Study: 19859806

Group type: EXPERIMENTAL
Intervention: All Stars prevention curriculum
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher dosage of All Stars
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher quality program delivery of All Stars
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Combination of higher dosage and higher quality delivery of All Stars
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 447
Study: 17921403

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 microg/d)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 15550992

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (Protopic)
Number of subjects: 0
Study: 11748093

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneous injection)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no etanercept)
Number of subjects: 13
Study: 9291905

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mechanical antipyresis alone
Number of subjects: 50
Study: 8332271

Group type: EXPERIMENTAL
Intervention: Enoximone (Group C: 0.5 mg/kg bolus and slow infusion at 10 gamma/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoximone (all groups)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20
Study: 2437095

Group type: COMPARATOR
Intervention: Acyclovir alone for five days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acyclovir for five days and isoprinosine for ten days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acyclovir for five days and levamisole twice weekly for three weeks
Number of subjects: 31
Study: 28965344

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HI - 80% of 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise with Blood Flow Restriction (LI-BFR - 20% of 1RM, 160 mmHg of BFR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON - no exercise or BFR)
Number of subjects: 10
Study: 25725192

Group type: EXPERIMENTAL
Intervention: Designed sport
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Working memory training
Number of subjects: 0
Study: 24813561

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 64
Study: 22274809

Group type: EXPERIMENTAL
Intervention: Once daily gonadotropin administration
Number of subjects: 213
Study: 19358785

Group type: EXPERIMENTAL
Intervention: Continuation of the same medications after acute treatment (mood stabilizer plus antidepressant) for 1 year
Number of subjects: 83
Study: 17469939

Group type: EXPERIMENTAL
Intervention: High-yield nicotine cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (denicotinized cigarette)
Number of subjects: 0
Study: 15870414

Group type: EXPERIMENTAL
Intervention: Single high-dose bolus tirofiban plus sirolimus-eluting stenting (n = 87)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard-dose abciximab plus bare-metal stenting (n = 88)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Single high-dose bolus tirofiban plus sirolimus-eluting stenting
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard-dose abciximab plus bare-metal stenting
Number of subjects: 175
Study: 11430966

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 1004
Study: 9927831

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.15 mg/kg intravenous dose followed by infusion of 3 micrograms/kg/min for 3 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (equivalent amount to diltiazem)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7919299

Group type: EXPERIMENTAL
Intervention: New esthesiometer used for diagnosis of hand-arm vibration syndrome
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 34
Study: 3281001

Group type: EXPERIMENTAL
Intervention: Intravariceal sclerotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 95
Study: 31116189

Group type: EXPERIMENTAL
Intervention: Suturing plus advanced‐platelet‐rich fibrin (A‐PRF+) plug
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suturing alone (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suturing plus haemostatic plug (HAEM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suturing plus leukocyte- and platelet-rich fibrin (L-PRF) plug
Number of subjects: 40
Study: 28720230

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (touching points within 1cm of main points)
Number of subjects: 50
Study: 25565165

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 30
Study: 24026598

Group type: EXPERIMENTAL
Intervention: Prednisolone + Pentoxifylline (40 mg prednisolone once a day and 400 mg pentoxifylline 3 times a day for 28 days)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Prednisolone + Placebo (40 mg prednisolone and matching placebo for 28 days)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Prednisolone + Pentoxifylline
Number of subjects: 270

Group type: COMPARATOR
Intervention: Prednisolone + Placebo
Number of subjects: 270
Study: 20860784

Group type: EXPERIMENTAL
Intervention: Attempted vaginal birth
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Elective caesarean section
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Visual analogue scale ratings
Number of subjects: 742
Study: 19643661

Group type: EXPERIMENTAL
Intervention: Short message service (SMS) intervention via cellular phone and Internet for 8 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 17365744

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND) responses by African American adolescents
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Fagerström Test for Nicotine Dependence (FTND) responses by White adolescents
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: MIMIC modeling
Number of subjects: 1139
Study: 15164108

Group type: EXPERIMENTAL
Intervention: Diet A (8.4% SFA of TEI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diet B (11% SFA of TEI)
Number of subjects: 25
Study: 11228275

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 0.75 mg
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 1.5 mg
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 3.0 mg
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 6.0 mg
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 8.0 mg
Number of subjects: 933

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg every 12 hours
Number of subjects: 933
Study: 9730093

Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard conservative methods (Control)
Number of subjects: 197
Study: 7815836

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) followed by intensive chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 0
Study: 2561145

Group type: EXPERIMENTAL
Intervention: Spirapril 12.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spirapril 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 5579492

Group type: EXPERIMENTAL
Intervention: Detergents containing proteolytic enzymes
Number of subjects: 4130

Group type: COMPARATOR
Intervention: Conventional detergents
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Enzyme products
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Clothes washed in enzyme products
Number of subjects: 4130
Study: 31238961

Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients
Number of subjects: 881

Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 881
Study: 28695606

Group type: EXPERIMENTAL
Intervention: Chrysin 50 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chrysin 75 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Ch-0)
Number of subjects: 20
Study: 26488111

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (brief hospitalization for medical stabilization and hospitalization for weight restoration to 90% expected body weight)
Number of subjects: 82
Study: 23856657

Group type: EXPERIMENTAL
Intervention: Treatment modalities (specific modalities not detailed)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Relaxation session content
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sudden gains
Number of subjects: 161
Study: 21873253

Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol (PEG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: magnesium citrate
Number of subjects: 50
Study: 19842887

Group type: EXPERIMENTAL
Intervention: Continuous ventilation during CPB
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard nonventilated CPB
Number of subjects: 46
Study: 17030532

Group type: EXPERIMENTAL
Intervention: 7-day antibiotic therapy (n = 34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 14-day antibiotic therapy (n = 35)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 7-day therapy for Staphylococcus aureus infection (n = 7)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 14-day therapy for Staphylococcus aureus infection (n = 7)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 7-day therapy for non-S. aureus infections
Number of subjects: 69

Group type: COMPARATOR
Intervention: 14-day therapy for non-S. aureus infections
Number of subjects: 69
Study: 14719048

Group type: EXPERIMENTAL
Intervention: Risperidone (2 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11352132

Group type: EXPERIMENTAL
Intervention: S1 (arrow pointing left or right) with color predictive of S2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control trials (third color arrow providing no valid information)
Number of subjects: 0
Study: 9595966

Group type: EXPERIMENTAL
Intervention: Metrifonate (0.5 mg/kg, 0.9 mg/kg, or 2.0 mg/kg for 2 weeks followed by maintenance doses of 0.2 mg/kg, 0.3 mg/kg, or 0.65 mg/kg for 10 weeks)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 1991950

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1.2 grams elemental calcium/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6340583

Group type: EXPERIMENTAL
Intervention: Combination of gentamicin sulfate and betamethasone phosphate
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 29385007

Group type: EXPERIMENTAL
Intervention: Alcohol (1.09 g ethanol·kg fat-free body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No alcohol (placebo; volume of alcohol replaced with water)
Number of subjects: 10
Study: 30917336

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 138
Study: 27407018

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 6 months
Number of subjects: 28
Study: 28336242

Group type: EXPERIMENTAL
Intervention: Pacritinib 400 mg once daily
Number of subjects: 327

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 327
Study: 24077205

Group type: COMPARATOR
Intervention: Pregabalin 50 mg every 8 hours orally (P group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg every 8 hours orally and Imipramine 5 mg every 12 hours orally (P-I group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg every 8 hours orally and Mirtazapine 7.5 mg every 12 hours orally (P-M group)
Number of subjects: 37
Study: 21430242

Group type: EXPERIMENTAL
Intervention: 25 g of NSP plus 22 g of RS/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: 25 g of NSP
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RS diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Entry diet
Number of subjects: 46
Study: 19150863

Group type: EXPERIMENTAL
Intervention: Protection Device (PD)
Number of subjects: 563

Group type: COMPARATOR
Intervention: No Protection Device (nonprotection)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Closed Cell Stent
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Open Cell Stent
Number of subjects: 563
Study: 17955440

Group type: EXPERIMENTAL
Intervention: PnCRM7 vaccine
Number of subjects: 852

Group type: COMPARATOR
Intervention: Day care‐attending unvaccinated children in PnCRM7 communities
Number of subjects: 852
Study: 15065825

Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporin (ACsA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11573049

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia and postoperative epidural morphine (group 2)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: General anesthesia and postoperative analgesia with parenteral opioids (group 1)
Number of subjects: 1021
Study: 10095403

Group type: EXPERIMENTAL
Intervention: Surgical ligament repair (group A)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-operative treatment (group B)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-operative treatment (group D)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Surgical treatment (group C)
Number of subjects: 109
Study: 7845808

Group type: EXPERIMENTAL
Intervention: Steroid membrane leads (30 micrograms of dexamethasone)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonsteroid membrane leads
Number of subjects: 90
Study: 2690631

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 1096903

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Indometacin (150 mg daily)
Number of subjects: 100
Study: 29304262

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 21
Study: 29137679

Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distal locking plate
Number of subjects: 0
Study: 26209242

Group type: EXPERIMENTAL
Intervention: Traditional surgery + PRF (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezosurgery + PRF (Group 3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional surgery (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional surgery (Group 4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional surgery + PRF (Group 2) vs Traditional surgery (Group 1)
Number of subjects: 20
Study: 23216707

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ABCB1 SNPs (C3435T, G2677T, C1236T)
Number of subjects: 96